NEW YORK ─ Beckman Coulter said on Thursday that it has gotten Emergency situation Use Authorization from the United States Fda for its Gain Access To Interleukin-6 (IL-6) immunoassay.
The Brea, California-based firm, part of Danaher, said the FDA licensed the fully automated assay for the detection of IL-6 levels in serum and plasma to help doctors recognize an extreme inflammatory response and determine the danger of intubation with mechanical ventilation in COVID-19 patients.
IL-6 is a multifunctional cytokine that may promote swelling in specific scientific conditions. IL-6 levels rise in patients with extreme COVID-19 and may contribute to an extreme inflammatory response, in some cases called a cytokine storm, Beckman Coulter said, mentioning a University of Oxford initial study.
“An assay that helps recognize patients at danger for breathing failure and intubation in the care path has the possible to considerably improve COVID-19 patient care and outcomes,” Shamiram Feinglass, chief medical officer of Beckman Coulter, said in a declaration. “In combination with scientific findings and the results of other laboratory testing, this assay offers clinicians with important information enabling them to make decisions on how to handle these seriously ill patients.”
Source: 360dx. com